Neuroinflammatory crosstalk in migraine: consolidated activity of rizatriptan and meloxicam in suppressing CGRP-induced nociception and COX-mediated inflammation.

Migraine is among the most frequently observed neurovascular malady affecting almost 1 billion people globally and is defined by frequent episodes of headache, accompanying neurological problems, and a markedly reduced standard of health. Migraine pathogenesis is directly linked to the CGRP (Calcitonin-gene-related-peptide), a strong vasodilating protein entangled in the exchange of nociceptor signals, and the cyclo-oxygenase (COX) enzymes, influencing inflammatory responses which aggravate migraine manifestations. Although COX inhibiting drugs as well as CGRP receptor blockers have therapeutical advantages when administered independently, however, they also have drawbacks, such as insufficient effectiveness or side effects, highlighting the necessity of synergistic approaches. In this regard, SYMBRAVO is a unique combinatorial pharmacological approach that aims to combine the advantages of COX-2 suppression and CGRP regulation. We have explored the molecular basis, pharmacological interaction, and clinical effectiveness of SYMBRAVO in this study, with a focus on how it can improve effectiveness, reduce adverse reactions and overcome barriers to single drug therapy. The results support a paradigm change towards integrated migraine therapy strategies that emphasize controlled, multi-pathway regulation.